Ersin ÖZEREN, Yahya GÜVENÇ, Adnan Yalçın DEMİRC, Çetin AKYOL, Pınar BAYRAM, Deniz BİLLUR, Sevim AYDIN, Hakan SEÇKİN, Kazım YİĞİTKANLI

What is the restorative effect of VEGF inhibitor bevacuzimab against subarachnoid hemorrhage in an experimental model?

Background/aim: This study investigated the effect of vascular endothelial growth factor (VEGF) inhibitor bevacuzimab (BVZ) on the rabbit basilar artery using an experimental subarachnoid hemorrhage (SAH) model. Materials and methods: Eighteen adult male New-Zealand white rabbits were randomly divided into three groups: a control group (n = 6), SAH group (n = 6), and SAH+BVZ group (n = 6). Experimental SAH was created by injecting autologous arterial blood into the cisterna magna. In the treatment group, the subjects were administered a daily dose of 10 mg/kg, intravenous BVZ for 2 days after the SAH. Basilar artery diameters were measured with magnetic resonance angiography (MRA) 72 h after the SAH in all groups. After 72 h, whole brains, including the upper cervical region, were obtained from all the animals after perfusion and fixation of the animal. The wall thickness, luminal area, and the apoptosis at the basilar arteries were evaluated in all groups. Results: BVZ significantly prevented SAH-induced vasospasm confirmed in vivo with MRA imaging with additional suppression of apoptosis on basilar artery wall. Conclusion: VEGF inhibition with BVZ has shown to have a vasospasm and apoptosis attenuating effect on basilar artery in a SAH model.Key words: Apoptosis, bevacizumab, subarachnoid hemorrhage, vasoconstriction, vascular endothelial growth factors

PDF

___

1. Demirci AY, Seckin H, Besalti O, Arikok AT, Yigitkanli T et al. Study the effects of zonisamide on fine structure of rabbit basilar artery and hippocampus in rabbit subarachnoid hemorrhage model. Acta Neurochirurgica (Wien) 2013; 155 (8): 1531-1537. doi: 10.1007/s00701-013-1726-9
2. Guvenc Y, Demirci A, Billur D, Aydin S, Ozeren E et al. Punica granatum L. juice attenuates experimental cerebral vasospasm in the rabbit subarachnoid hemorrhage model: a basilar artery morphometric study and apoptosis. Journal of Neurological Surgery. Part A, Central European Neurosurgery 2017; 78 (2): 124-131. doi: 10.1055/s-0036-1584906
3. Feng SQ, Zong SY, Liu JX, Chen Y, Xu R et al. VEGF antagonism attenuates cerebral ischemia/reperfusion-induced injury via inhibiting endoplasmic reticulum stress-mediated apoptosis. Biological and Pharmaceutical Bulletin 2019; 42 (5): 692-702. doi: 10.1248/bpb.b18-00628
4. Borel CO, McKee A, Parra A, Haglund MM, Solan A et al. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke 2003; 34: 427-433. doi: 10.1161/01.STR.0000053848.06436.AB
5. McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002; 51 (5): 1128-1135. doi: 10.1097/00006123-200211000-00005
6. Yan J, Chen C, Lei J, Yang L, Wang K et al. 2-methoxyestradiol reduces cerebral vasospasm after 48 hours of experimental subarachnoid hemorrhage in rats. Experimental Neurology 2006; 202 (2): 348-356. doi: 10.1016/j.expneurol.2006.06.009
7. Baizabal-Carvallo JF, Alonso-Juárez M, Salas I. Pretruncal subarachnoid hemorrhage and high cerebral blood flow velocities with bevacizumab therapy. Clinical Neuropharmacology 2010; 33 (5): 268-269. doi: 10.1097/ WNF.0b013e3181f59f19
8. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95 (4): 1030- 1037. doi: 10.1161/01.CIR.95.4.1030
9. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14 (11): 1131-1138. doi: 10.1634/theoncologist.2009-0121
10. Testai FD, Aiyagari V, Hillmann M, Amin-Hanjani S, Dawson G et al. Proof of concept: endogenous antiangiogenic factors predict the occurrence of symptomatic vasospasm post subarachnoid hemorrhage. Neurocritical Care 2011; 15 (3): 416-420. doi: 10.1007/s12028-011-9559-y
11. Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor. Molecular Biology of the Cell 2010; 21 (3): 377-379. doi: 10.1091/mbc.E09-07-0591
12. Liu L, Fujimoto M, Kawakita F, Nakano F, Imanaka-Yoshida K et al. Anti-vascular endothelial growth factor treatment suppresses early brain injury after subarachnoid hemorrhage in mice. Molecular Neurobiology 2016; 53 (7): 4529-4538. doi: 10.1007/s12035-015-9386-9
13. Nakano F, Kawakita F, Liu L, Nakatsuka Y, Nishikawa H et al. Anti-vasospastic effects of epidermal growth factor receptor inhibitors after subarachnoid hemorrhage in mice. Molecular Neurobiology 2018; 56 (7): 4730-4740. doi: 10.1007/s12035- 018-1400-6
14. Jośko J. Cerebral angiogenesis and expression of VEGF after subarachnoid hemorrhage (SAH) in rats. Brain Research 2003; 981 (1-2): 58-69. doi: 10.1016/s0006-8993(03)02920-2
15. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? NeuroOncology 2008; 10 (4): 624-630. doi: 10.1215/15228517-2008- 010
16. Khasraw M, Holodny A, Goldlust SA, DeAngelis LM. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology 2012; 23 (2): 458-63. doi: 10.1093/annonc/ mdr148
17. Seidel C, Hentschel B, Simon M, Schnell O, Heese O et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. Journal of Neurology 2013; 260 (3): 847-855. doi: 10.1007/s00415-012- 6718-9
18. Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. Journal of Neuro-Oncology 2011; 105 (2): 281-289. doi: 10.1007/s11060-011-0579-4
19. Lin X, Daras M, Pentsova E, Nolan CP, Gavrilovic IT et al. Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. Neuro-Oncology Practice 2017; 4 (1): 24-28. doi: 10.1093/nop/npw008
20. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology 2009; 27 (28): 4733-4740. doi: 10.1200/JCO.2008.19.8721
21. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010; 15 (2): 130-141. doi: 10.1634/ theoncologist.2009-0252
22. Lukas RV, Goldenberg F, Nicholas MK. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. Journal of Clinical Neuroscience 2012; 19 (9): 1310-1311. doi: 10.1016/j.jocn.2011.11.027